GeneDx beats Q4 estimates with non-GAAP EPS $0.14 on revenue $121M, reaffirms 2026 guidance

 

 while expanding into new markets

• Q4 revenue was $121M, up 27% year-over-year, with full-year revenue $428M and FY 2025 revenue $427.5M.
• Non-GAAP EPS of $0.14 declined 82% year over year even as revenue grew 27% in Q4.
• Exome and genome revenue reached $104M in Q4, up 32% year-over-year; organic growth 42%, underscoring accelerating testing demand.
https://finviz.com/quote.ashx?t=WGS&p=d